Drug intelligence / Profile preview

candenizumab

Development stage: Unknown
Lead developer: Fujian Medical University

Overview

Candenizumab is an investigational drug being studied for the treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma. It is currently being evaluated in combination with lenvatinib and the SOX chemotherapy regimen (S-1 plus oxaliplatin) in clinical trials. The precise mechanism of action, molecular target, and modality of candenizumab have not been publicly disclosed as of June 2025. Its development appears to be led by academic institutions rather than a pharmaceutical company, with Fujian Medical University listed as a lead sponsor in clinical research[5].

Beyond the preview

Go deeper on candenizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on candenizumab.

Explore the full profile